Navigation Links
Through 2018, Five New Drugs Will Launch for the Treatment of Myelodysplastic Syndromes
Date:2/6/2013

BURLINGTON, Mass., Feb. 6, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018, five new drugs will launch for the treatment of myelodysplastic syndromes (MDS), three of which are expected to offer much-needed second-line therapeutic options in the hypomethylating agent (HMA)-refractory higher-risk MDS population. Currently, there is only one curative treatment for MDS -- allogeneic hematopoietic stem cell transplant (HSCT). However, old age and poor general performance status classifies approximately 75 percent of patients as ineligible for this treatment.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

Between 2004 and 2006, the U.S. MDS market expanded when the first drug therapy options were approved for the indication -- azacitidine (Celgene's Vidaza), lenalidomide (Celgene's Revlimid) and decitabine (Eisai/MGI Pharma's Dacogen). No new therapies have been approved in the United States for MDS since 2006; only azacitidine has been approved for MDS in Europe, although experts believe an EU approval for lenalidomide is imminent.

According to Niche Markets and Rare Diseases: Myelodysplastic Syndromes, azacitidine is the leading therapeutic option for the disease in both the U.S. and Europe. Decision Resources anticipates expansion of MDS therapeutic options with the approval of five drugs between 2014-2018: oral azacitidine for transfusion-dependent lower-risk MDS; Onconova/Baxter's intravenous formulation of rigosertib (Estybon) for HMA-refractory higher-risk MDS; Merck's vorinostat (Zolinza) for combination therapy with azacitidine in higher-risk MDS; Cyclacel's oral sapacitabine for HMA-refractory higher-risk MDS; and GlaxoSmithKline's eltrombopag (Revolade) for HMA-refractory higher-risk MDS, with a focal goal of reducing thrombocytopenia. Onconova also has an oral formulation of rigosertib in development for lower-risk patients.

"The near-term MDS drug market will grow modestly as lenalidomide obtains approval in Europe, but the next wave of noteworthy market growth will come between 2014 and 2018," said Decision Resources Vice President Kim Crowell . "While experts acknowledge that the approvals of azacitidine and lenalidomide were groundbreaking, they also report significant remaining unmet need in MDS. Citing the dearth of second-line options for higher-risk MDS patients, experts are hopeful that several Phase II and III drugs will provide valuable alternative therapeutic options, although they do not expect any drug during the next decade to completely shift or uproot the MDS therapeutic landscape. Improving overall survival, without sacrificing quality of life, is the key therapeutic goal in higher risk MDS patients, while functional quality of life via hematologic improvement is the primary goal in lower-risk patients."

About Myelodysplastic Syndromes

Myelodysplastic Syndromes is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Breakthrough Procedure Provides Relief for Acid Reflux
2. The Treatment Landscape for Thyroid Carcinoma Will Change Dramatically Through 2021
3. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
4. Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need
5. Executives guide entrepreneurs through science business maze
6. Seeing Life Through Many Lenses: Different Ophthalmic Lenses for Different Lifestyles
7. Brazilian, Indian and Chinese Orthopedic Markets to See Strong Growth Through 2017
8. Breakthrough Research Could Create Sea Change in Global HIV Diagnosis: New Handheld Mobile Device Performs Laboratory-Quality HIV Testing
9. Maximizing the Effectiveness of Market Research Groups through Outsourcing and Automation
10. New Breakthrough Treatment For Evaporative Dry Eye Disease Introduced By Dry Eye Specialist, Mark R. Mandel, M.D.
11. Elseviers Clinical Pharmacology Now Accessible Through Elsevier Infobutton
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... that offers insurance and financial preparation services, is providing an update on a ... organization. , Rock City Rescue is a locally recognized nonprofit that provides shelter ...
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
Breaking Medicine News(10 mins):